Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Autor:	Andrew J. Armstrong, Richard Wenstrup, Russell Z. Szmulewitz, Daniel C. Danila, Emmanuel S. Antonarakis, David M. Nanus, Daniel J. George, Yamini Gore, Alisa Tubbs, Akash Roy, Qian Yang, Susan Halabi, Santosh Gupta
Rok vydání:	2023
DOI:	10.1158/1078-0432.22820158.v1
Popis:	CTC biomarker group incidence by PSMA optimal cutoff (AR-v7, chromosomal instability (CIN), and neuroendocrine (NE) at baseline (N=97) and progression (N=57).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e66639d28b0e9f542671badbfd82151 https://doi.org/10.1158/1078-0432.22820158.v1 Zobrazit plný text záznamu